3SBio (HK:1530) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
3SBio’s subsidiary, Shenyang Sunshine, has entered into a strategic agreement with Haihe Biopharma to exclusively commercialize Paclitaxel Oral Solution in Mainland China and Hong Kong. This collaboration involves Shenyang Sunshine making initial and milestone payments to RMX Biopharma, which will continue overseeing clinical trials and development. Investors are advised to remain cautious as the product’s successful commercialization is not guaranteed.
For further insights into HK:1530 stock, check out TipRanks’ Stock Analysis page.
